Eyenovia, Inc. (NASDAQ:), a biopharmaceutical company specializing in ophthalmic diseases, announced its financial results for the first quarter ended March 31, 2024, during their...
BMO Capital Markets hiked its 2024 price target for the on Wednesday, citing sustained robust market momentum. Initially, the investment bank set the...
